Literature DB >> 2118324

Antibacterial activity of lomefloxacin in a pharmacokinetic in vitro model.

C Rustige1, B Wiedemann.   

Abstract

An in vitro model simulating two-compartment pharmacokinetics was used to study the antibacterial activity of lomefloxacin after single oral doses of 200 and 400 mg. Lomefloxacin produced reliable bactericidal activity against gram-negative aerobic bacteria and staphylococci. Bacterial strains for which MICs were less than 0.5 microgram/ml were inhibited with both dosing schedules. Doubling the dose from 200 to 400 mg increased the bactericidal activity only against Pseudomonas aeruginosa. Against Enterococcus faecalis lomefloxacin showed no effect. Selection of resistant variants during the simulation of treatment was observed with Staphylococcus aureus and P. aeruginosa.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2118324      PMCID： PMC171766          DOI： 10.1128/AAC.34.6.1107

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  6 in total

1.  Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses.

Authors:  P J Morrison; T G Mant; G T Norman; J Robinson; R L Kunka
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

2.  Pharmacokinetics and tissue penetration of orally administered lomefloxacin.

Authors:  J W Stone; J M Andrews; J P Ashby; D Griggs; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

3.  Antibacterial effects of cefroxadine, cephalexin and cephradine in a new in vitro pharmacokinetic model.

Authors:  P Schneider; W Tosch; M Maurer; O Zak
Journal:  J Antibiot (Tokyo)       Date:  1982-07       Impact factor: 2.649

4.  New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity.

Authors:  S Grasso; G Meinardi; I de Carneri; V Tamassia
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

5.  Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.

Authors:  C C Sanders; W E Sanders; R V Goering; V Werner
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

6.  In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones.

Authors:  N X Chin; A Novelli; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191
  6 in total
  4 in total

1.  Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model.

Authors:  A A Firsov; S N Vostrov; A A Shevchenko; G Cornaglia
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

2.  Comparison of the pharmacodynamic properties of quinolones.

Authors:  B Wiedemann; C Rustige-Wiedemann; B Kratz
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 3.  Lomefloxacin clinical pharmacokinetics.

Authors:  C D Freeman; D P Nicolau; P P Belliveau; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

4.  Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.

Authors:  Beate Henrichfreise; Irith Wiegand; Ingeborg Luhmer-Becker; Bernd Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  2007-08-06       Impact factor: 5.191
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.